Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer.
González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M, Mendez-Vidal MJ, Pinto A, Sastre J, de Prado DS, Terrasa J, Vázquez S, Powles T, Beyer J, Castellano D, Del Muro XG; Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group. González-Billalabeitia E, et al. Eur Urol Focus. 2017 Apr;3(2-3):280-286. doi: 10.1016/j.euf.2016.07.002. Epub 2016 Jul 18. Eur Urol Focus. 2017. PMID: 28753776 Review.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group. Climent MA, et al. Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002. Epub 2012 Jan 29. Crit Rev Oncol Hematol. 2012. PMID: 22285697
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Castellano D, Antón Aparicio LM, Esteban E, Sánchez-Hernández A, Germà JR, Batista N, Maroto P, Pérez-Valderrama B, Luque R, Méndez-Vidal MJ; cabazitaxel EAP study. Castellano D, et al. Expert Opin Drug Saf. 2014 Sep;13(9):1165-73. doi: 10.1517/14740338.2014.939583. Epub 2014 Jul 7. Expert Opin Drug Saf. 2014. PMID: 25001524 Clinical Trial.
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J. Climent MÁ, et al. Crit Rev Oncol Hematol. 2015 Nov;96(2):308-18. doi: 10.1016/j.critrevonc.2015.05.019. Epub 2015 Jun 8. Crit Rev Oncol Hematol. 2015. PMID: 26100652 Review.
New advances in genitourinary cancer: evidence gathered in 2014.
Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A. Suárez C, et al. Cancer Metastasis Rev. 2015 Sep;34(3):443-64. doi: 10.1007/s10555-015-9577-x. Cancer Metastasis Rev. 2015. PMID: 26227584 Review.
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Pérez-Valderrama B, et al. Ann Oncol. 2016 Apr;27(4):706-11. doi: 10.1093/annonc/mdv601. Epub 2015 Dec 9. Ann Oncol. 2016. PMID: 26658889 Free article. Clinical Trial.
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. Lainez N, et al. BMC Cancer. 2016 Feb 22;16:135. doi: 10.1186/s12885-016-2084-9. BMC Cancer. 2016. PMID: 26906039 Free PMC article.
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, García-Foncillas J. Cebrián A, et al. Sci Rep. 2017 Jan 24;7:41371. doi: 10.1038/srep41371. Sci Rep. 2017. PMID: 28117391 Free PMC article.
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group). Puente J, et al. Oncotarget. 2017 May 2;8(18):30410-30421. doi: 10.18632/oncotarget.16494. Oncotarget. 2017. PMID: 28423742 Free PMC article.
62 results